Orphalan Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Orphalan Sa (US): 1 reconciled FDA prescription therapies, $3.3M 2024 CMS Part D & Medicaid spend, and $13,752 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$1.7M
California HCAI SB 17 FilingsSpecialty launch notice ($13,752 intro WAC)